Kathleen M Giacomini

List of Publications by Year
in descending order

143	13,085	38742	23533
papers	citations	50 h-index	111 g-index

151	151	151	12185
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Membrane transporters in drug development. Nature Reviews Drug Discovery, 2010, 9, 215-236.	46.4	2,886
2	Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. Journal of Clinical Investigation, 2007, 117, 1422-1431.	8.2	786
3	SLC transporters as therapeutic targets: emerging opportunities. Nature Reviews Drug Discovery, 2015, 14, 543-560.	46.4	584
4	Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity. Cancer Research, 2006, 66, 8847-8857.	0.9	384
5	Cloning and Functional Expression of a Human Liver Organic Cation Transporter. Molecular Pharmacology, 1997, 51, 913-921.	2.3	374
6	Metformin pathways. Pharmacogenetics and Genomics, 2012, 22, 820-827.	1.5	366
7	The concentrative nucleoside transporter family, SLC28. Pflugers Archiv European Journal of Physiology, 2004, 447, 728-734.	2.8	348
8	Renal Transporters in Drug Development. Annual Review of Pharmacology and Toxicology, 2013, 53, 503-529.	9.4	267
9	Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 5902-5907.	7.1	265
10	Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 5896-5901.	7.1	224
11	cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8902-8907.	7.1	222
12	OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 9983-9988.	7.1	203
13	Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenetics and Genomics, 2009, 19, 497-504.	1.5	202
14	Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. Clinical Pharmacology and Therapeutics, 2018, 104, 890-899.	4.7	185
15	Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics and Genomics, 2002, 12, 395-405.	5.7	183
16	Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenetics and Genomics, 2010, 20, 687-699.	1.5	175
17	Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5480-5485.	7.1	173
18	Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins. Molecular Cancer Therapeutics, 2011, 10, 531-539.	4.1	172

#	Article	IF	Citations
19	Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nature Genetics, 2016, 48, 1055-1059.	21.4	165
20	Profiling of a Prescription Drug Library for Potential Renal Drugâ€“Drug Interactions Mediated by the Organic Cation Transporter 2. Journal of Medicinal Chemistry, 2011, 54, 4548-4558.	6.4	141
21	Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drugâ€Drug Interaction Evaluation: Perspectives From the International Transporter Consortium. Clinical Pharmacology and Therapeutics, 2018, 104, 836-864.	4.7	141
22	Discovery of Potent, Selective Multidrug and Toxin Extrusion Transporter 1 (MATE1, SLC47A1) Inhibitors Through Prescription Drug Profiling and Computational Modeling. Journal of Medicinal Chemistry, 2013, 56, 781-795.	6.4	131
23	Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 15810-15815.	7.1	120
24	The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statinâ€Associated Musculoskeletal Symptoms. Clinical Pharmacology and Therapeutics, 2022, 111, 1007-1021.	4.7	120
25	Metformin Pharmacogenomics: Current Status and Future Directions. Diabetes, 2014, 63, 2590-2599.	0.6	112
26	Transporters Involved in Metformin Pharmacokinetics and Treatment Response. Journal of Pharmaceutical Sciences, 2017, 106, 2245-2250.	3.3	108
27	A genome-wide association study of bronchodilator response in Latinos implicates rare variants. Journal of Allergy and Clinical Immunology, 2014, 133, 370-378.e15.	2.9	105
28	Organic Anion Transporter 2 (SLC22A7) Is a Facilitative Transporter of cGMP. Molecular Pharmacology, 2008, 73, 1151-1158.	2.3	103
29	Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium. Clinical Pharmacology and Therapeutics, 2018, 104, 803-817.	4.7	99
30	Transport of Paraquat by Human Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Family. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 695-700.	2.5	98
31	Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics Journal, 2009, 9, 127-136.	2.0	94
32	Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). Pharmacogenetics and Genomics, 2005, 15, 201-209.	1.5	93
33	Targeted Disruption of Organic Cation Transporter 3 Attenuates the Pharmacologic Response to Metformin. Molecular Pharmacology, 2015, 88, 75-83.	2.3	88
34	The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. American Journal of Physiology - Renal Physiology, 2006, 290, F905-F912.	2.7	87
35	Molecular Modeling and Ligand Docking for Solute Carrier (SLC) Transporters. Current Topics in Medicinal Chemistry, 2013, 13, 843-856.	2.1	85
36	Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. Nature Reviews Drug Discovery, 2017, 16, 70-70.	46.4	80

#	Article	IF	Citations
37	Towards Quantitation of the Effects of Renal Impairment and Probenecid Inhibition on Kidney Uptake and Efflux Transporters, Using Physiologically Based Pharmacokinetic Modelling and Simulations. Clinical Pharmacokinetics, 2014, 53, 283-293.	3.5	79
38	Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3). Molecular Pharmaceutics, 2015, 12, 4301-4310.	4.6	79
39	Identification and Quantitative Assessment of Uremic Solutes as Inhibitors of Renal Organic Anion Transporters, OAT1 and OAT3. Molecular Pharmaceutics, 2016, 13, 3130-3140.	4.6	79
40	Organic Cation Transporters Modulate the Uptake and Cytotoxicity of Picoplatin, a Third-Generation Platinum Analogue. Molecular Cancer Therapeutics, 2010, 9, 1058-1069.	4.1	74
41	Arginine 454 and Lysine 370 Are Essential for the Anion Specificity of the Organic Anion Transporter, rOAT3â€. Biochemistry, 2001, 40, 5511-5520.	2.5	70
42	A Comprehensive Analysis of Ontogeny of Renal Drug Transporters: mRNA Analyses, Quantitative Proteomics, and Localization. Clinical Pharmacology and Therapeutics, 2019, 106, 1083-1092.	4.7	69
43	Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient. Clinical Pharmacology and Therapeutics, 1980, 27, 665-670.	4.7	62
44	Interaction of nucleoside analogues with the sodium-nucleoside transport system in brush border membrane vesicles from human kidney. Pharmaceutical Research, 1993, 10, 423-426.	3.5	61
45	The activities of drug inactive ingredients on biological targets. Science, 2020, 369, 403-413.	12.6	61
46	Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1;) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	6.4	58
47	Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. Pharmacogenetics and Genomics, 2009, 19, 770-780.	1.5	56
48	Functional Genetic Diversity in the High-Affinity Carnitine Transporter OCTN2 (SLC22A5). Molecular Pharmacology, 2006, 70, 1602-1611.	2.3	55
49	LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5000-5006.	2.2	54
50	Rapid Method To Determine Intracellular Drug Concentrations in Cellular Uptake Assays: Application to Metformin in Organic Cation Transporter 1-Transfected Human Embryonic Kidney 293 Cells. Drug Metabolism and Disposition, 2016, 44, 356-364.	3.3	54
51	Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1). Journal of Medicinal Chemistry, 2018, 61, 7358-7373.	6.4	54
52	LAT-1 activity of meta-substituted phenylalanine and tyrosine analogs. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2616-2621.	2.2	53
53	Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drugâ€“Drug Interaction and Associated Biomarker Levels in Healthy Volunteers. Clinical and Translational Science, 2019, 12, 388-399.	3.1	53
54	Molecular Determinants of Substrate Selectivity in Na+-dependent Nucleoside Transporters. Journal of Biological Chemistry, 1997, 272, 28845-28848.	3.4	51

#	Article	IF	Citations
55	Gene Expression Profiling of Transporters in the Solute Carrier and ATP-Binding Cassette Superfamilies in Human Eye Substructures. Molecular Pharmaceutics, 2013, 10, 650-663.	4.6	50
56	The effect of probenecid on the renal elimination of cimetidine. Clinical Pharmacology and Therapeutics, 1989, 45, 444-452.	4.7	49
57	Pharmacogenomics and Patient Care: One Size Does Not Fit All. Science Translational Medicine, 2012, 4, 153ps18.	12.4	49
58	High Selectivity of the Î³-Aminobutyric Acid Transporter 2 (GAT-2, SLC6A13) Revealed by Structure-based Approach. Journal of Biological Chemistry, 2012, 287, 37745-37756.	3.4	49
59	The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. Clinical Pharmacology and Therapeutics, 1989, 46, 408-419.	4.7	48
60	Reduced Renal Clearance of Cefotaxime in Asians with a Low-Frequency Polymorphism of OAT3 (SLC22A8). Journal of Pharmaceutical Sciences, 2013, 102, 3451-3457.	3.3	47
61	The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. Clinical Pharmacokinetics, 2016, 55, 711-721.	3.5	47
62	The role of ATM in response to metformin treatment and activation of AMPK. Nature Genetics, 2012, 44, 359-360.	21.4	46
63	Organic cation transporter 1 (OCT1) modulates multiple cardiometabolic traits through effects on hepatic thiamine content. PLoS Biology, 2018, 16, e2002907.	5.6	45
64	Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). Pharmacogenetics and Genomics, 2007, 17, 773-782.	1.5	43
65	The pharmacokinetics of the enantiomers of atenolol. Clinical Pharmacology and Therapeutics, 1989, 45, 403-410.	4.7	42
66	Role of Organic Cation Transporter 1, OCT1 in the Pharmacokinetics and Toxicity of cis-Diammine(pyridine)chloroplatinum(II) and Oxaliplatin in Mice. Pharmaceutical Research, 2011, 28, 610-625.	3.5	42
67	Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities. Clinical Pharmacology and Therapeutics, 2020, 107, 57-61.	4.7	42
68	Organic cation transporter 3 (Oct3) is a distinct catecholamines clearance route in adipocytes mediating the beiging of white adipose tissue. PLoS Biology, 2019, 17, e2006571.	5.6	41
69	Genomic Characterization of Metformin Hepatic Response. PLoS Genetics, 2016, 12, e1006449.	3.5	41
70	Molecular Mechanisms for Species Differences in Organic Anion Transporter 1, OAT1: Implications for Renal Drug Toxicity. Molecular Pharmacology, 2018, 94, 689-699.	2.3	40
71	Opportunities and challenges for the computational interpretation of rare variation in clinically important genes. American Journal of Human Genetics, 2021, 108, 535-548.	6.2	40
72	Emerging Clinical Importance of Hepatic Organic Cation Transporter 1 (OCT1) in Drug Pharmacokinetics, Dynamics, Pharmacogenetic Variability, and Drug Interactions. Clinical Pharmacology and Therapeutics, 2018, 103, 758-760.	4.7	39

#	Article	IF	Citations
73	A conserved role of the insulin-like signaling pathway in diet-dependent uric acid pathologies in Drosophila melanogaster. PLoS Genetics, 2019, 15, e1008318.	3.5	39
74	Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16009-16018.	7.1	39
75	Prediction and validation of enzyme and transporter off-targets for metformin. Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42, 463-475.	1.8	37
76	A research roadmap for next-generation sequencing informatics. Science Translational Medicine, 2016, 8, 335ps10.	12.4	37
77	Genome-Wide Discovery of Drug-Dependent Human Liver Regulatory Elements. PLoS Genetics, 2014, 10, e1004648.	3.5	36
78	A New Era in Pharmacovigilance: Toward Realâ€World Data and Digital Monitoring. Clinical Pharmacology and Therapeutics, 2021, 109, 1197-1202.	4.7	36
79	Genetic Variation in the Proximal Promoter of ABC and SLC Superfamilies: Liver and Kidney Specific Expression and Promoter Activity Predict Variation. PLoS ONE, 2009, 4, e6942.	2.5	34
80	Genetic Variants in CPA6 and PRPF31 Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. Diabetes, 2018, 67, 1428-1440.	0.6	32
81	Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt. Clinical Pharmacology and Therapeutics, 1980, 28, 417-424.	4.7	31
82	Effect of hemodialysis on propoxyphene and norpropoxyphene concentrations in blood of anephric patients*. Clinical Pharmacology and Therapeutics, 1980, 27, 508-514.	4.7	31
83	Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans. Frontiers in Pharmacology, 2016, 7, 135.	3.5	28
84	ITC Commentary on Metformin Clinical Drugâ€“Drug Interaction Study Design That Enables an Efficacyâ€• and Safetyâ€Based Dose Adjustment Decision. Clinical Pharmacology and Therapeutics, 2018, 104, 781-784.	4.7	28
85	A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome. Pharmacogenetics and Genomics, 2015, 25, 82-92.	1.5	27
86	The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers. Clinical Pharmacokinetics, 2016, 55, 495-506.	3.5	27
87	Emerging Roles of the Human Solute Carrier 22 Family. Drug Metabolism and Disposition, 2022, 50, 1193-1210.	3.3	26
88	PharmGKB summary. Pharmacogenetics and Genomics, 2017, 27, 420-427.	1.5	25
89	Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response. Clinical Pharmacology and Therapeutics, 2018, 103, 233-242.	4.7	25
90	GenEpi: gene-based epistasis discovery using machine learning. BMC Bioinformatics, 2020, 21, 68.	2.6	25

#	Article	IF	Citations
91	Drugâ€“nutrient interactions: discovering prescription drug inhibitors of the thiamine transporter ThTR-2 (SLC19A3). American Journal of Clinical Nutrition, 2020, 111, 110-121.	4.7	24
92	The Effect of Uremic Solutes on the Organic Cation Transporter 2. Journal of Pharmaceutical Sciences, 2017, 106, 2551-2557.	3.3	23
93	Computational Discovery and Experimental Validation of Inhibitors of the Human Intestinal Transporter OATP2B1. Journal of Chemical Information and Modeling, 2017, 57, 1402-1413.	5.4	23
94	Unraveling the functional role of the orphan solute carrier, SLC22A24 in the transport of steroid conjugates through metabolomic and genome-wide association studies. PLoS Genetics, 2019, 15, e1008208.	3.5	23
95	Genomeâ€Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol. Clinical Pharmacology and Therapeutics, 2019, 106, 623-631.	4.7	23
96	Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care, 2021, 44, 2673-2682.	8.6	23
97	Genetic variants of human organic anion transporter 4 demonstrate altered transport of endogenous substrates. American Journal of Physiology - Renal Physiology, 2010, 299, F767-F775.	2.7	22
98	Genetic variation in human aquaporins and effects on phenotypes of water homeostasis. Human Mutation, 2008, 29, 1108-1117.	2.5	21
99	Deorphaning a solute carrier 22 family member, SLC22A15, through functional genomic studies. FASEB Journal, 2020, 34, 15734-15752.	0.5	21
100	Stereoselective interactions of organic cations with the organic cation transporter in OK cells. Pharmaceutical Research, 1993, 10, 1169-1173.	3.5	20
101	Effect of Concentration-Dependent Binding to Plasma Proteins on the Pharmacokinetics and Pharmacodynamics of Disopyramide. Clinical Pharmacokinetics, 1984, 9, 42-48.	3.5	16
102	Sorting of rat SPNT in renal epithelium is independent of N-glycosylation. Pharmaceutical Research, 2003, 20, 319-323.	3.5	16
103	Interactions of Oral Molecular Excipients with Breast Cancer Resistance Protein, BCRP. Molecular Pharmaceutics, 2020, 17, 748-756.	4.6	16
104	Drugs in COVIDâ€19 Clinical Trials: Predicting Transporterâ€Mediated Drugâ€Drug Interactions Using In Vitro Assays and Realâ€World Data. Clinical Pharmacology and Therapeutics, 2021, 110, 108-122.	4.7	16
105	New and Emerging Research on Solute Carrier and ATP Binding Cassette Transporters in Drug Discovery and Development: Outlook From the International Transporter Consortium. Clinical Pharmacology and Therapeutics, 2022, 112, 540-561.	4.7	16
106	Correction for Volume Shift during Equilibrium Dialysis by Measurement of Protein Concentration. Pharmaceutical Research, 1984, 01, 179-181.	3.5	15
107	Unmet needs: Research helps regulators do their jobs. Science Translational Medicine, 2015, 7, 315ps22.	12.4	15
108	OCT1 in hepatic steatosis and thiamine disposition. Cell Cycle, 2015, 14, 283-284.	2.6	15

#	Article	IF	Citations
109	Human Concentrative Nucleoside Transporter 3 (hCNT3, SLC28A3) Forms a Cyclic Homotrimer. Biochemistry, 2017, 56, 3475-3483.	2.5	15
110	Taurine transport in cultured choroid plexus. Pharmaceutical Research, 1997, 14, 406-409.	3.5	14
111	Drug Metabolites Potently Inhibit Renal Organic Anion Transporters, OAT1 and OAT3. Journal of Pharmaceutical Sciences, 2021, 110, 347-353.	3.3	14
112	l-Type amino acid transporter 1 activity of 1,2,3-triazolyl analogs of l-histidine and l-tryptophan. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2254-2258.	2.2	13
113	Functional and structural analysis of rare SLC2A2 variants associated with Fanconiâ€Bickel syndrome and metabolic traits. Human Mutation, 2019, 40, 983-995.	2.5	13
114	High Throughput Screening of a Prescription Drug Library for Inhibitors of Organic Cation Transporter 3, OCT3. Pharmaceutical Research, 2022, 39, 1599-1613.	3.5	13
115	Expression of a renal Na+-nucleoside cotransport system (N2) in Xenopus laevis oocytes. Pflugers Archiv European Journal of Physiology, 1994, 427, 381-383.	2.8	12
116	Pharmacogenetics of Antidiabetic Drugs. Advances in Pharmacology, 2018, 83, 361-389.	2.0	12
117	Formycin B elimination from the cerebrospinal fluid of the rat. Pharmaceutical Research, 1993, 10, 611-615.	3.5	11
118	Impact of Pharmaceutical Excipients on Oral Drug Absorption: A Focus on Intestinal Drug Transporters. Clinical Pharmacology and Therapeutics, 2019, 105, 323-325.	4.7	10
119	Clinical Pharmacology & Therapeutics 2030. Clinical Pharmacology and Therapeutics, 2020, 107, 13-16.	4.7	8
120	Scientific considerations for global drug development. Science Translational Medicine, 2020, 12, .	12.4	8
121	Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics. Clinical and Translational Science, 2021, 14, 1431-1443.	3.1	8
122	Renal transport of drugs: an overview of methodology with application to cimetidine. Pharmaceutical Research, 1988, 05, 465-471.	3.5	7
123	Stereoselective binding of disopyramide to plasma proteins. Pharmaceutical Research, 1988, 05, 316-318.	3.5	7
124	Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins. British Journal of Pharmacology, 2021, 178, 1459-1474.	5.4	7
125	Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein. AAPS Journal, 2021, 23, 106.	4.4	7
126	Research Projects Supported by the <scp>University of California, San Francisco</scp>â€Stanford Center of Excellence in Regulatory Science and Innovation. Clinical Pharmacology and Therapeutics, 2019, 105, 815-818.	4.7	6

#	Article	IF	Citations
127	Expanding Precompetitive Multisector Collaborations to Advance Drug Development and Pharmacogenomics. Clinical Pharmacology and Therapeutics, 2020, 107, 96-101.	4.7	6
128	Advancing Precision Medicine Through the New Pharmacogenomics Global Research Network. Clinical Pharmacology and Therapeutics, 2021, 110, 559-562.	4.7	6
129	Effect of Probenecid on the Pharmacokinetics and Pharmacodynamics of Procainamide. Journal of Clinical Pharmacology, 1991, 31, 429-432.	2.0	5
130	Mechanisms of 5-fluorouracil (5-FU) transport in isolated rabbit choroid plexus tissue slices. Pharmaceutical Research, 1996, 13, 1276-1278.	3.5	5
131	Neural production of kynurenic acid in Caenorhabditis elegans requires the AAT-1 transporter. Genes and Development, 2020, 34, 1033-1038.	5.9	5
132	A Critical Overview of the Biological Effects of Excipients (Part I): Impact on Gastrointestinal Absorption. AAPS Journal, 2022, 24, 60.	4.4	5
133	Cimetidine elimination from the cerebrospinal fluid of the rat. Pharmaceutical Research, 1988, 05, 628-633.	3.5	3
134	The Effects of Genetic Mutations and Drugs on the Activity of the Thiamine Transporter, SLC19A2. AAPS Journal, 2021, 23, 35.	4.4	2
135	In Vitro Evaluation of Excipients as Inhibitors of Human Intestinal Pâ€glycoprotein. FASEB Journal, 2019, 33, 814.3.	0.5	2
136	Novel Technologies Enable Mechanistic Understanding and Modeling of Drug Exposure and Response. Clinical Pharmacology and Therapeutics, 2020, 107, 1045-1047.	4.7	1
137	A Tribute to Professor Per Artursson - Scientist, Explorer, Mentor, Innovator, and Giant in Pharmaceutical Research. Journal of Pharmaceutical Sciences, 2021, 110, 2-11.	3.3	1
138	Pharmacogenomic mechanisms of drug toxicity. , 2022, , 303-322.		1
139	Mechanisms and genetics of drug transport. , 2022, , 213-239.		1
140	Verapamil interacts stereoselectively with the muscarinic receptor. Pharmaceutical Research, 1985, 02, 94-95.	3.5	0
141	SLCO1B1 Variation and Methotrexate Disposition in Children with Acute Lymphoblastic Leukemia: The Importance of Rare Variants in Pharmacogenetics. Blood, 2011, 118, 571-571.	1.4	0
142	Germline Genetic Polymorphisms Are Associated with Disease-Free Survival in Adults with Acute Myeloid Leukemia (AML): A Genomewide Association Study From the Pgrn-Riken Global Alliance.. Blood, 2012, 120, 2548-2548.	1.4	0
143	Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673â€“2682. Diabetes Care, 2022, 45, e82-e83.	8.6	0